お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:痙縮 - 市場調査、疫学、市場予測 2028年
市場調査レポート
商品コード
534852

痙縮 - 市場調査、疫学、市場予測 2028年

Spasticity - Market Insight, Epidemiology and Market Forecast - 2028

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
痙縮 - 市場調査、疫学、市場予測 2028年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の痙縮市場について調査し、疾病の概要や現行の治療法、新薬のプロファイル、主要7カ国の市場動向、疫学的予測、市場規模、有病数・罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 イントロダクション

第2章 痙縮市場の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要:痙縮

  • イントロダクション
  • 症状
  • 病因
  • 危険因子
  • 病態生理学
  • 診断
  • 治療

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国における痙縮の総有病数・罹患数
  • 主要7カ国における痙縮の総有病数 - 国別

第5章 痙縮の疫学:国別

  • 米国
    • 仮定と理論的根拠
    • 痙縮の有病数・罹患数
    • 痙縮の症例数:病型別
    • 痙縮の症例数:性別
    • 痙縮の診断数
    • 痙縮の治療可能な症例数
  • EU5カ国
    • 仮定と理論的根拠
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 現行治療

  • 治療アルゴリズム
  • 治療ガイドライン

第7章 アンメットニーズ

第8章 上市済み治療薬

  • 医薬品 A
    • 医薬品概要
    • 作用機序
    • 規制のマイルストーン
    • 長所と短所
    • 製品プロファイル
  • 医薬品 B

第9章 パイプライン治療薬

第10章 キークロスコンペティション

第11章 新薬

  • 医薬品 C
    • 医薬品の概要
    • 臨床試験の詳細
    • 安全性と有効性のプロファイル
    • 長所と短所
    • パイプライン開発動向
    • 製品プロファイル
  • 医薬品 D

第12章 痙縮:主要7カ国市場の分析

  • 市場規模
  • 上市済み治療薬の市場シェア
  • 治療薬の売上高:製品別

第13章 痙縮:国別市場分析

  • 米国
    • 市場規模
    • 上市済み治療薬の市場シェア
    • 治療薬の売上高:製品別
    • 新薬とその市場への影響
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第14章 市場成長要因

第15章 市場の障壁

第16章 付録

第17章 調査手法

  • 出典

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Spasticity in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Spasticity in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Spasticity in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Spasticity in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Spasticity in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Spasticity in United States (2016-2028)
  • Table 7: Treatable Cases of the Spasticity in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Spasticity in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Spasticity in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Spasticity in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Spasticity in Germany (2016-2028)
  • Table 12: Treatable Cases of the Spasticity in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Spasticity in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Spasticity in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Spasticity in France (2016-2028)
  • Table 16: Diagnosed Cases of the Spasticity in France (2016-2028)
  • Table 17: Treatable Cases of the Spasticity in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Spasticity in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Spasticity in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Spasticity in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Spasticity in Italy (2016-2028)
  • Table 22: Treatable Cases of the Spasticity in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Spasticity in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Spasticity in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Spasticity in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Spasticity in Spain (2016-2028)
  • Table 27: Treatable Cases of the Spasticity in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Spasticity in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Spasticity in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Spasticity in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Spasticity in UK (2016-2028)
  • Table 32: Treatable Cases of the Spasticity in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Spasticity in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Spasticity in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Spasticity in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Spasticity in Japan (2016-2028)
  • Table 37: Treatable Cases of the Spasticity in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Spasticity in USD MM (2016-2028)
  • Table 42:7MM- Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Spasticity in USD MM (2016-2028)
  • Table 45: United States-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Spasticity in USD MM (2016-2028)
  • Table 48: Germany-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Spasticity in USD MM (2016-2028)
  • Table 51: France-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Spasticity in USD MM (2016-2028)
  • Table 54: Italy-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Spasticity in USD MM (2016-2028)
  • Table 57: Spain-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Spasticity in USD MM (2016-2028)
  • Table 60:UK-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Spasticity in USD MM (2016-2028)
  • Table 63: Japan-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Spasticity by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Spasticity in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Spasticity in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Spasticity in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Spasticity in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Spasticity in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Spasticity in United States (2016-2028)
  • Figure 7: Treatable Cases of the Spasticity in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Spasticity in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Spasticity in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Spasticity in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Spasticity in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Spasticity in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Spasticity in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Spasticity in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Spasticity in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Spasticity in France (2016-2028)
  • Figure 17: Treatable Cases of the Spasticity in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Spasticity in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Spasticity in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Spasticity in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Spasticity in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Spasticity in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Spasticity in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Spasticity in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Spasticity in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Spasticity in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Spasticity in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Spasticity in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Spasticity in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Spasticity in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Spasticity in UK (2016-2028)
  • Figure 32: Treatable Cases of the Spasticity in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Spasticity in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Spasticity in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Spasticity in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Spasticity in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Spasticity in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Spasticity in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 45: United States-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 51: France-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 60:UK-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Spasticity in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Spasticity by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Spasticity by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0218

DelveInsight's "Spasticity - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Spasticity epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Spasticity Understanding and Treatment Algorithm

The market report provides the overview of the Spasticity by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Spasticity Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Spasticity in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Spasticity Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Spasticity Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Spasticity market.

Spasticity Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Spasticity Report Insights

  • Patient Population in Spasticity
  • Therapeutic Approaches in Spasticity
  • Spasticity Pipeline Analysis
  • Spasticity Market Size and Trends
  • Spasticity Market Opportunities
  • Impact of upcoming Therapies in Spasticity

Spasticity Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Spasticity Report Assessment

  • Current Treatment Practices in Spasticity
  • Unmet Needs in Spasticity
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Spasticity market
  • Organize sales and marketing efforts by identifying the best opportunities for Spasticity market
  • To understand the future market competition in the Spasticity market.

Table of Contents

1. Report Introduction

2. Spasticity Market Overview at a Glance

  • 2.1. Market Share Distribution of Spasticity in 2016
  • 2.2. Market Share Distribution of Spasticity in 2028

3. Disease Background and Overview: Spasticity

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Spasticity in 7MM
  • 4.3. Total Prevalent Patient Population of Spasticity in 7MM - By Countries

5. Epidemiology of Spasticity by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Spasticity
    • 5.1.3. Sub-Type Specific cases of the Spasticity *
    • 5.1.4. Sex- Specific Cases of the Spasticity *
    • 5.1.5. Diagnosed Cases of the Spasticity
    • 5.1.6. Treatable Cases of the Spasticity
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Spasticity
    • 5.4.3. Sub-Type Specific cases of the Spasticity *
    • 5.4.4. Sex- Specific Cases of the Spasticity *
    • 5.4.5. Diagnosed Cases of the Spasticity
    • 5.4.6. Treatable Cases of the Spasticity
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Spasticity
    • 5.5.3. Sub-Type Specific cases of the Spasticity *
    • 5.5.4. Sex- Specific Cases of the Spasticity *
    • 5.5.5. Diagnosed Cases of the Spasticity
    • 5.5.6. Treatable Cases of the Spasticity
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Spasticity
    • 5.6.3. Sub-Type Specific cases of the Spasticity *
    • 5.6.4. Sex- Specific Cases of the Spasticity *
    • 5.6.5. Diagnosed Cases of the Spasticity
    • 5.6.6. Treatable Cases of the Spasticity
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Spasticity
    • 5.7.3. Sub-Type Specific cases of the Spasticity *
    • 5.7.4. Sex- Specific Cases of the Spasticity *
    • 5.7.5. Diagnosed Cases of the Spasticity
    • 5.7.6. Treatable Cases of the Spasticity
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Spasticity
    • 5.8.3. Sub-Type Specific cases of the Spasticity *
    • 5.8.4. Sex- Specific Cases of the Spasticity *
    • 5.8.5. Diagnosed Cases of the Spasticity
    • 5.8.6. Treatable Cases of the Spasticity
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Spasticity
    • 5.9.3. Sub-Type Specific cases of the Spasticity *
    • 5.9.4. Sex- Specific Cases of the Spasticity *
    • 5.9.5. Diagnosed Cases of the Spasticity
    • 5.9.6. Treatable Cases of the Spasticity

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Spasticity

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Spasticity

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Spasticity : 7MM Market Analysis

  • 12.1. 7MM Market Size of Spasticity
  • 12.2. 7MM Percentage Share of drugs marketed for Spasticity
  • 12.3. 7MM Market Sales of Spasticity by Products

13. Spasticity : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Spasticity in United States
    • 13.1.2. Percentage Share of drugs marketed for Spasticity in United States
    • 13.1.3. Market Sales of Spasticity by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Spasticity in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Spasticity in Germany
      • 13.2.1.3. Market Sales of Spasticity by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Spasticity in France
      • 13.2.2.2. Percentage Share of drugs marketed for Spasticity in France
      • 13.2.2.3. Market Sales of Spasticity by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Spasticity in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Spasticity in Italy
      • 13.2.3.3. Market Sales of Spasticity by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Spasticity in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Spasticity in Spain
      • 13.2.4.3. Market Sales of Spasticity by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Spasticity in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Spasticity in United Kingdom
      • 13.2.5.3. Market Sales of Spasticity by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Spasticity in Japan
    • 13.3.2. Percentage Share of drugs marketed for Spasticity in Japan
    • 13.3.3. Market Sales of Spasticity by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.